Key regions: Australia, Japan, United States, Germany, Europe
The medical industry in Nepal has been developing in recent years, with the Anti-Coagulants market being no exception.
Customer preferences: Nepal has a growing elderly population, which has led to an increase in the number of patients with cardiovascular diseases. As a result, there has been a higher demand for Anti-Coagulants medication, which helps prevent blood clots that can lead to strokes and heart attacks.
Trends in the market: The Anti-Coagulants market in Nepal has seen a shift towards newer drugs, such as direct oral anticoagulants (DOACs), which offer a more convenient and safer alternative to traditional warfarin therapy. This trend is in line with the global market, where DOACs have been gaining popularity due to their ease of use and fewer side effects. Additionally, there has been an increase in the number of generic versions of Anti-Coagulants drugs available in Nepal, which has made the medication more affordable for patients.
Local special circumstances: The healthcare system in Nepal is still developing, which has led to challenges in the distribution and availability of medication in remote areas. This has resulted in a higher demand for Anti-Coagulants medication in urban areas, where access to healthcare is more readily available. Additionally, there is a lack of awareness about cardiovascular diseases and their prevention in Nepal, which has led to a delay in diagnosis and treatment for some patients.
Underlying macroeconomic factors: Nepal has been experiencing economic growth in recent years, which has led to an increase in healthcare spending. This has resulted in more funding for medical research and development, which has contributed to the development of newer and more effective Anti-Coagulants medication. Additionally, the Nepalese government has been working towards improving healthcare infrastructure and increasing access to healthcare services, which has also contributed to the growth of the Anti-Coagulants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
